Senseonics Holdings Inc. (SENS) Stock Sees Surge with Groundbreaking Glucose Monitoring System

Senseonics (SENS) has a unique continuous glucose monitoring system, Eversense 365, approved for a full year of use, setting it apart from traditional systems. Analyst Sean Lee initiated coverage with a Buy rating and $1.10 price target. 2 analysts predict an average price target of $2.00, a 282.04% upside from the current price of $0.52. The company reported a 24% increase in net revenue for Q1 2025 and announced the integration of Eversense 365 with SQL's Twist Automated Insulin Delivery System.